Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents-a Pragmatic Randomized Controlled Trial

NCT07307235 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.

NCT NCT07307235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07307235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents-a Pragmatic Randomized Controlled Trial
Lead sponsor
Shanghai Zhongshan Hospital
Phase
Phase 4
Overall status
Recruiting
Start date
December 13, 2025
Completion date
December 30, 2027
Enrollment
1,316 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes